News
Seres (MCRB) Q2 Loss Narrows 34%
Seres Therapeutics (NASDAQ:MCRB), a clinical-stage biotech focused on microbiome therapeutics, released its second quarter 2025 earnings on August 6, 2025. The main highlight was a narrowing net
Artiva (ARTV) Q2 Loss Widens 19.7%
Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotechnology company pioneering allogeneic natural killer (NK) cell therapies for autoimmune diseases, released its financial results for the
Brookdale (BKD) Q2 Revenue Rises 4.6%
Brookdale Senior Living (NYSE:BKD), the nationwide operator of senior living communities, released its results for Q2 2025 on August 6, 2025. The period saw a notable jump in occupancy and stronger
Certara (CERT) Q2 Revenue Jumps 12%
Certara (NASDAQ:CERT), a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue
Upstream Bio (UPB) Q2 R&D Soars 169%
Upstream Bio (NASDAQ:UPB), a biotechnology company developing new therapies for respiratory diseases, released its second quarter 2025 results on August 6, 2025. The main headline was rapid
CRH (CRH) Q2 Revenue Rises 6%
CRH (NYSE:CRH), the global building materials firm, reported its earnings release for the second quarter of fiscal 2025 on August 6, 2025. The company delivered GAAP revenue of $10.2 billion and
Boeing Defense Workers Just Went on Strike. Should Investors Be Concerned?
More than 3,200 Boeing (NYSE: BA) workers at the company's St. Louis-area defense factories went on strike Monday after the International Association of Machinists and Aerospace Workers (the IAM
Inspired (INSE) Q2 Revenue Jumps 7%
Inspired Entertainment (NASDAQ:INSE), a gaming technology provider covering casino systems, virtual sports, and interactive gaming content, released its results on August 6, 2025. The business
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6
Pyxus (PYYX) Q1 Revenue Falls 20%
Pyxus International (OTC:PYYX), a global leaf tobacco merchant and supply chain manager, released its first-quarter fiscal 2026 results on August 6, 2025. Revenue (GAAP) for Q1 FY2026 was $508.8
Paycom (PAYC) Q2 Revenue Rises 10.5%
Paycom (NYSE:PAYC), a leading provider of cloud-based human capital management (HCM) software, reported second quarter 2025 results on August 6, 2025. The company posted GAAP revenue of $483.6
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its
Dayforce (DAY) Q2 EPS Jumps 27%
Dayforce (NYSE:DAY), a global provider of human capital management (HCM) software, released its second-quarter 2025 earnings on August 6, 2025. The company reported notable earnings and revenue
EverCommerce (EVCM) Q2 Revenue Up 5%
EverCommerce (NASDAQ:EVCM), a software firm specializing in digital solutions for service-based small and medium-sized businesses (SMBs), released its results for Q2 2025 on August 6, 2025. The
Procept (PRCT) Q2 Revenue Jumps 48%
Procept BioRobotics (NASDAQ:PRCT), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia (BPH) treatment, posted second-quarter 2025 results on
Verra Mobility (VRRM) Q2 Revenue Up 6%
Verra Mobility (NASDAQ:VRRM), a leader in smart mobility technology serving commercial fleets and government agencies, released its second-quarter results on August 6, 2025. The headline news from
Zentalis (ZNTL) Q2 Loss Narrows 70%
Zentalis Pharmaceuticals (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news
Astec (ASTE) Q2 EPS Jumps 59%
Astec Industries (NASDAQ:ASTE), a leading manufacturer of equipment for road building and aggregate processing, reported results for Q2 2025 on August 6, 2025. In this report, the company delivered
Mativ (MATV) Q2 EPS Jumps 83%
Mativ (NYSE:MATV), a manufacturer of specialty materials and solutions for filtration, packaging, and adhesives, released its Q2 2025 results on August 6, 2025. The company outpaced analyst
Soleno (SLNO) Q2 Revenue Jumps 30%
Soleno Therapeutics (NASDAQ:SLNO), a biotech company focused on rare disease treatments, posted its inaugural commercial revenue following the U.S. launch of VYKAT XR for Prader-Willi syndrome
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
NewAmsterdam Pharma (NASDAQ:NAMS), a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, delivered its Q2 2025 earnings report on August 6
Vaxcyte (PCVX) Q2 Loss Widens 11%
Vaxcyte (NASDAQ:PCVX), a biotechnology company specializing in next-generation vaccines, reported its second quarter 2025 results on August 6, 2025. The company reported a GAAP net loss per share of
Symbotic (SYM) Q3 Revenue Jumps 26%
Symbotic (NASDAQ:SYM), a warehouse automation technology provider, delivered its third quarter fiscal 2025 earnings on August 6, 2025. Symbotic achieved GAAP revenue of $592 million for Q3 FY2025
Extreme (EXTR) Q4 Revenue Jumps 20%
Extreme Networks (NASDAQ:EXTR), a provider of cloud-managed networking solutions and services, reported its Q4 FY2025 financial results on August 6, 2025. The headline news: The company beat Wall
Amtech (ASYS) Q3 Revenue Beats by 15%
Amtech Systems (NASDAQ:ASYS), a supplier of thermal processing and semiconductor equipment, reported its fiscal third quarter results on August 6, 2025. The company’s earnings release highlighted a